Production of the recombinant human granulocyte colony-stimulating factor in Escherichia coli using a new vector
The granulocyte colony-stimulating factor (G-CSF) is a hematopoietic cytokine that has been widely used as a therapeutic agent for treating neutropenia in oncology patients and to improving the immune system of immunocompromised patients. The recombinant human G-CSF (rhG-CSF) has been commercially produced in E. coli. In this work, we develop a process to obtain rhG-CSF in bioreactor with the new expression vector pARKAN-I and to refold this protein from the inclusion bodies. The construction pARKAN-I/rhG-CSF presented high stability before and after induction (100% kanamycin resistant colonies), even without antibiotic in the culture. rhG-CSF production was estimated as 383 mg.L-1. The dilution refolding method was highly efficient (90% of refolding) and eliminated several impurities. The pH adjustment after refolding increased the rhG-CSF purity to 78%, which could facilitate the subsequent chromatographic step.